InfuSystem FY2022 revenue up 7% to record $109.9M, but adjusted EBITDA down 14%

InfuSystem Holdings, Inc

Full year net revenue $109.9M (+7% YoY); Q4 revenue $28.8M (+9% YoY).
Adjusted EBITDA $20.7M FY2022, down 14% YoY; Q4 adj. EBITDA $5.5M, down 16%.
Net income for year less than $0.1M; Q4 diluted EPS $0.01.
Guides FY2023 revenue growth 8-10% (~$118-121M); adj. EBITDA margin >19%.
Launched wound care JV with Sanara Medtech; biomedical services contract ramp-up continues.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

InfuSystem Holdings, Inc reported fourth quarter and full year ended December 31, 2022 results: revenue Net revenues totaled $109.9 million, net income Net income of less than $0.1 million, EPS $0.01 per diluted share. Guidance reaffirmed.

Period: fourth quarter and full year ended December 31, 2022
Revenue: Net revenues totaled $109.9 million
Net income: Net income of less than $0.1 million
EPS: $0.01 per diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2022 Full Year 2022 vs. Full Year 2021: Record Net Revenues: $109.9 million, a 7% increase

View on SEC.gov

50 earnings releases filed in the last 30 days. Browse all earnings releases →

InfuSystem Holdings, Inc filing history →

Source: SEC EDGAR

accession 0001628280-23-007945

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.